東陽光藥(01558.HK)放棄2015戰略合作協議下的優先購買權
格隆匯3月19日丨東陽光藥(01558.HK)發佈公吿,近日,公司收到深圳東陽光實業的通知,深圳東陽光實業控股的廣東東陽光藥業有限公司為聚焦於抗感染、抗腫瘤代謝領域的核心產品線項目的研發,計劃以包括但不限於獨佔許可等方式將其具有獨立知識產權的低氧誘導因子—脯氨酰羥化酶抑制劑、可溶性鳥苷酸環化酶刺激劑、鹽皮質激素受體拮抗劑、法尼醇X受體激動劑、5-HT再攝取抑制劑和5-HT1A受體部分激動劑、FLT3高選擇性抑制劑、Axl和Mer雙靶點小分子酪氨酸激酶抑制劑共7個在研項目的研發及商業化權利進行對外授予,並詢問公司是否行使2015戰略合作協議和補充協議下的優先購買權。
考慮到擬許可項目目前均處於臨牀前研究階段至臨牀I期階段內,項目研發週期較長,預計研發投入大,研發風險較高,且擬許可項目與公司的適應症領域配置、產品管線佈局及未來發展規劃關聯性不大,如收購該項目產品後續還需要投入大量時間和資金建設、完善相關適應症領域的生產車間和商業推廣團隊,整體成本投入大而收益回報不確定,因此公司擬放棄該項目的優先購買權。
上述產品尚處於臨牀前研究階段至臨牀I期階段,能否獲准進入臨牀試驗階段或能否完成臨牀試驗具有不確定性。公司本次放棄優先購買權事項由本公司獨立非執行董事進行審閲、考慮及決定,公司獨立非執行董事在綜合考慮了公司適應症領域配置、產品管線佈局及未來發展規劃與收購後研發、生產、推廣的時間、資金投入及相關投資風險等因素作出的決策,並考慮公司產品佈局與之關聯性不大,且不會對公司的生產經營、財務狀況產生重大影響,不存在損害公司及中小股東權益的情況下,同意公司放棄該項目優先購買權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.